News | News By Subject | News by Disease News By Date | Search News

Angioedema News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Stock Plunges as Biocryst (BCRX)'s Angioedema Drug Flunks Phase II Study     2/8/2016
FDA Bestows Breakthrough Therapy Designation on Dyax Corp. (DYAX)'s HAE Drug As Suitors Circle     7/7/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Pharming Group (PHGUF.PK), Salix (SLXP) Wins FDA Approval For Ruconest®     7/17/2014
Pharming Group (PHGUF.PK)-Santarus Inc. (SNTS) Ruconest Phase III Study Meets Primary Endpoint     11/7/2012
FDA Lifts Temporary Hold on ViroPharma Incorporated (VPHM) Treatment     9/21/2012
FDA Approves Shire plc's Firazyr to Treat Acute Attacks of Hereditary Angioedema     8/25/2011
Pharming Group (PHGUF.PK) Discontinues Funding of DNage     1/31/2011
Shire plc: FIRAZYR FAST-3 Phase 3 Study Endpoints Statistically Significant Results for Hereditary Angioedema     12/1/2010
Dyax Corp. (DYAX), CMIC Co., Ltd. to Develop, Market Angioedema Drug; Dyax to Receive $4 Million Upfront and Eligible for $102 Million More in Milestone Payments     9/30/2010
Data from Dyax Corp. (DYAX)'s First Phase 3 Trial (EDEMA3(R)) for KALBITOR(R) (ecallantide) Published in The New England Journal of Medicine     8/5/2010
Pharming Group (PHGUF.PK) Receives Positive Opinion From European Medicines Evaluation Agency On Rhucin     6/24/2010
Dyax Corp. (DYAX) (JOBS) Gets FDA Approval For Genetic Disorder Drug     12/3/2009

News from Around the Web

Press Releases
FDA Accepts CSL Behring's Biologics License Application For First Subcutaneous Prophylactic Therapy To Prevent Hereditary Angioedema Attacks     8/30/2016
KalVista Pharmaceuticals Announces Initiation Of A Phase 1 Clinical Trial Of KVD818 For The Treatment Of Hereditary Angioedema     8/11/2016
Biocryst (BCRX) Announces Initiation Of The Apex-1 Clinical Trial Of BCX7353 For Hereditary Angioedema     8/11/2016
U.S. FDA Approves CSL Behring's Berinert As The First And Only Pediatric Treatment For Hereditary Angioedema (HAE)     7/18/2016
Global Blood Therapeutics (GBT) Reports Recent Business Progress And Provides Fourth Quarter And Year-End 2015 Financial Results     3/29/2016
Pharming Group (PHGUF.PK) Release: European Medicines Agency Reaffirms Important Health Benefits And Safety Of Ruconest For Patients With Hereditairy Angioedema     12/7/2015
Dyax (DYAX) Presents Phase 1b DX-2930 Data At American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting     11/10/2015
Dyax (DYAX) Announces Cancellation Of Research And Development Day     11/2/2015
Dyax Corp. (DYAX) Announces Third Quarter 2015 Financial Results     10/29/2015
Biocryst Pharmaceuticals (BCRX) Announces Successful Phase I Clinical Trial Of BCX7353     10/8/2015
Biocryst Pharmaceuticals (BCRX) Announces Completion Of Patient Enrollment In OPuS-2: A Clinical Trial Of Avoralstat In Patients With HAE     10/8/2015
Dyax Corp. (DYAX) Receives Positive Opinion For Orphan Medicinal Product Designation In The European Union For DX-2930 For The Treatment Of Hereditary Angioedema     9/30/2015
Dyax Corp. (DYAX) Receives FDA Breakthrough Therapy Designation For DX-2930 For Prevention Of Attacks Of Hereditary Angioedema     7/7/2015
Biocryst Pharmaceuticals (BCRX) Announces Initiation Of A Phase I Clinical Trial Of BCX7353 For The Treatment Of Hereditary Angioedema     5/13/2015
Biocryst Pharmaceuticals (BCRX) Release: FDA Grants Fast Track Designation For BCX4161 For The Treatment Of Hereditary Angioedema     1/26/2015

//-->